26 May 2016

SQS win 22m worth of orders

Ben Jaglom

German software testing concern SQS Software Quality Systems (SQS) has announced a raft of contract wins worth a total of 22 million.

The AIM-quoted concern declared the contract wins will be coming with a deal to provide 'test management, automation and functional testing' to a 'large European logistics company' This contract is said to be worth 10 million over the next two years. Another deal is to provide the same services but to the French operations of a 'global insurance provider' worth 5 million. Its other contracts include wins with 'four leading retail companies' worth a total of 3.3 million, three public sector contracts worth 2.5 million, a contract with a 'multi-national media company' worth 500,000 and a deal with a 'major UK utilities company' costing €300,000.

SQS' chief executive officer Rudolf van Megen enthused that the win 'highlight the compelling value propositions' of SQS' products and services adding that it provides the company with confidence for the expansion of our regional presence and market share.'

Analysts at house broker Arbuthnot held their forecasts. The broker expects pre-tax profits of 11.4 million (EPS: 28.96 cents) on sales of 178.7 million for the year to December 2011. In 2012 it predicts profits of 13.6 million (EPS: 33.6 cents) on revenue of 199.6 million.

Growth Company Investor recommended shares in SQS this January as a buy/hold at 225p and they have since lost 11.3 per cent, currently trading at 199.5p. Though the latest wins have not moved forecasts they are nonetheless encouraging steps. We retain our buy/hold rating.

Tags: Business in Germany, German Technology, Independent software testing, Quality management services

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Motif Bio and the ticking timebomb

The recently published O'Neill report on antimicrobial resistance shows it to be a ticking timebomb. Resistance to antibiotics raises the prospect of 10 million deaths a year by 2050. This is a big opportunity for AIM listed Motif Bio (AIM: MTFB).      

Make mine a double!

Fevertree Drinks (AIM: FEVR) has been one of the most spectacular new issues on AIM in recent years, rising 412 per cent from the float price in late 2014. Today’s trading update served to emphasise why the shares are doing so well and drove them up another 15 per cent.

Fox Marble might be worth the wait 

Fox Marble (AIM: FOX) has raised £2 million through a placing at 10p. The funds will be mainly used to complete its long-delayed marble processing factory in Kosovo. Fox has an exciting story but unfortunately is lagging way behind its original roadmap to profitability.

Business as usual at XL Media 

XL Media (AIM: XLM) has announced the result of its strategic review. I hope no one was holding their breath, because the conclusion is to carry on as usual! The good news is that trading is said to have ‘maintained its excellent start to 2016’.

A Quantum of solace

Quantum Pharma (AIM: QP.) committed the cardinal sin of overpromising and under-delivering during its first year on AIM. New products took longer to come through the regulatory process than expected, which caused downgrades and a share price collapse from a high of 172p last June to the current 58p. However results for the financial year which ended in January suggest the company is getting to grips with the problems in its Niche Pharmaceuticals division.

Elecosoft constructs a strategy for growth 

Elecosoft (AIM: ELCO) is a specialist software company serving architects and builders. It used to be a much larger business but sold out of its building materials businesses four years ago to focus on its software arm. The challenge now is to generate some revenue growth and move off a sales plateau which has been in place since then.

More News